TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 1.5nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 2nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 3nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 3nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
TargetTafazzin/Transcriptional enhancer factor TEF-3 [217-434]/Transcriptional coactivator YAP1 [60-100](Human)
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 3nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand Info
